Nathan Cherrington

Center Director
Research Focus Group Membership: 
Research Focus Group 3
Education: 

PhD, North Carolina State University, 1997, Toxicology
BS, Brigham Young University, 1993, Zoology

College Affiliations: 

College of Pharmacy
College of Public Health

Research Interests: 

Individual Variability in Drug Response and Adverse Drug Reactions,Transporter Regulation and Molecular Toxicology

Environmental Health Research & Expertise: 

My laboratory has been focused on the effect of liver disease on the ability of an individual to metabolize and eliminate drugs and xenobiotics, as well as the mechanisms by which drug metabolizing enzymes and transporters are regulated by cellular stress. A major focus of my laboratory has been investigating the mechanisms of altered expression and activity of the major drug metabolizing enzymes and transporters during the progressive stages of nonalcoholic fatty liver disease. We have identified changes in the expression and functionality of several drug metabolizing enzymes in both rodent models and the human disease. We have recently discovered alterations in the expression and localization of key drug transporters in NASH resulting in altered disposition of drugs and xenobiotics. A major thrust of this work is an effort to identify patients at greater risk of developing adverse drug reactions due to altered pharmacokinetics and overall exposure. This work has led to the development of a non-invasive biomarker in a cohort of pediatric nonalcoholic fatty liver disease patients that specifically identifies those with NASH. My laboratory is now poised at the forefront of understanding drug disposition alterations in liver disease.

Select Publications

2015

Lake, A. D., P. Novak, P. Shipkova, N. Aranibar, D. G. Robertson, M. D. Reily, L. D. Lehman-McKeeman, R. R. Vaillancourt, and N. J. Cherrington, "Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease.", Amino Acids, vol. 47, issue 3, pp. 603-15, 2015 Mar. PubMed PMCID: PMC4329055  PMID: 25534430
Dzierlenga, A. L., J. D. Clarke, T. L. Hargraves, G. R. Ainslie, T. W. Vanderah, M. F. Paine, and N. J. Cherrington, "Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.", J Pharmacol Exp Ther, vol. 352, issue 3, pp. 462-70, 2015 Mar. PubMed PMCID: PMC4352592  PMID: 25512370
Canet, M. J., R. N. Hardwick, A. D. Lake, A. L. Dzierlenga, J. D. Clarke, M. J. Goedken, and N. J. Cherrington, "Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.", Drug Metab Dispos, vol. 43, issue 2, pp. 266-72, 2015 Feb. PubMed PMCID: PMC4293398  PMID: 25488932
Canet, M. J., M. D. Merrell, B. G. Harder, J. M. Maher, T. Wu, A. J. Lickteig, J. P. Jackson, D. D. Zhang, M. Yamamoto, and N. J. Cherrington, "Identification of a functional antioxidant response element within the eighth intron of the human ABCC3 gene.", Drug Metab Dispos, vol. 43, issue 1, pp. 93-9, 2015 Jan. PubMed PMCID: PMC4279086  PMID: 25349122

2014

Kyriakides, M., R. N. Hardwick, Z. Jin, M. J. Goedken, E. Holmes, N. J. Cherrington, and M. Coen, "Systems level metabolic phenotype of methotrexate administration in the context of non-alcoholic steatohepatitis in the rat.", Toxicol Sci, vol. 142, issue 1, pp. 105-16, 2014 Nov. PubMed PMCID: PMC4226764  PMID: 25145655